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T cells have the capacity to induce tumor re-
gression, which provides the rationale for their 
exploitation in the therapy of cancer (1–9). To 
execute their antitumor activities, it is thought 
that T cells need to physically engage target 
cells within the tumor microenvironment, which 
results in the recognition of tumor-associated 
antigens in the context of MHC class I or II 
molecules. As a prerequisite, T cells must home 
to tumor sites via the blood stream, and then 
traverse the interstitial space to eventually reach 
their targets. Besides tumor cells, the tumor micro-
environment harbors a variety of host-derived 
cells, such as endothelial cells, fi  broblasts, in-
nate and adaptive immune cells, as well as 
  extracellular matrix (ECM) fi  bers, cytokines, 
and other mediators. All of these components 
may be involved in shaping the migratory and 
interactive behavior of tumor-infi  ltrating T 
lymphocytes (TILs).
Although recent advances in noninvasive 
imaging approaches, such as bioluminescence 
and magnetic resonance imaging, have made 
possible longitudinal studies of the traffi   cking 
of eff  ector T cells into tumors at the population 
level (10, 11), the precise behavior of TILs at 
the single cell level within the three-dimen-
sional context of the tumor microenvironment 
is unknown. Thus, fundamental questions re-
garding the critical fi  nal steps of tumor immu-
nity have remained unanswered. For example, 
it has been speculated that T cells follow che-
motactic gradients within infl  ammatory sites, 
including the tumor microenvironment, im-
plying directed migration at the population 
level (12–15). However, this hypothesis has 
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The tumor microenvironment is composed of an intricate mixture of tumor and host-
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pletely understood. Furthermore, the spatiotemporal conditions of TIL locomotion through 
the tumor stroma, as a prerequisite for establishing contact with target cells, have not been 
analyzed. These shortcomings limit the rational design of immunotherapeutic strategies 
that aim to overcome tumor-immune evasion. We have used two-photon microscopy to 
determine, in a dynamic manner, the requirements leading to tumor regression by TILs. Key 
observations were that TILs migrated randomly throughout the tumor microenvironment 
and that, in the absence of cognate antigen, they were incapable of sustaining active 
migration. Furthermore, TILs in regressing tumors formed long-lasting (≥30 min), cognate 
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rophages, suggesting tumor antigen cross-presentation by these cells. Our results demon-
strate that recognition of cognate antigen within tumors is a critical determinant of 
optimal TIL migration and target cell interactions, and argue against TIL guidance by long-
range chemokine gradients.
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not been tested within intact tumors. In addition, we do not 
know the exact identity of cells targeted by TILs. Although 
tumor cells are likely candidates, TILs may also interact with 
stromal cells, such as macrophages and dendritic cells, cross-
presenting tumor-associated antigens (16). Interactions with 
stromal cells may not only be important for the activation of 
TILs within tumors leading, for example, to cytokine pro-
duction, but may also directly contribute to tumor regression 
through stromal cell destruction (17). Finally, the dynamics 
of TIL-target cell interactions have not been studied. Al-
though in vitro studies have shown that T cells undergo 
long-term, cognate antigen–dependent interactions with tu-
mor cells (18–20), cellular behavior in vivo may follow 
diff  erent rules. Thus, although it is not known whether TIL-
target cell interactions are short- or long-lived, the duration 
of interactions may be important for the formation of the 
  immunologic synapse. A detailed understanding of these open 
questions at the cellular and molecular level may help to 
  optimize therapeutic regimens, as T cell responses could be 
manipulated to increase therapeutic effi   cacy.
In this study we investigated the behavior of TILs using 
two-photon microscopy (21–34) in combination with a 
transgenic mouse strain, DPEGFP, in which T cells express the 
GFP. We found that TILs migrated randomly before engag-
ing directly with tumor cells and macrophages. Furthermore, 
cognate antigen at the target site was an important regulatory 
element of the migration and interaction of TILs.
RESULTS
Migratory behavior of endogenous naive T cells within LNs
Thus far, two-photon imaging of T cell immune responses 
has been exclusively performed with adoptively transferred 
antigen-specifi   c T cells. We have recently developed a 
transgenic mouse strain, DPEGFP, with GFP expression in 
all T cells. In these mice, GFP is driven under the control of 
the distal and proximal CD4 enhancers and CD4 promoter 
(35, 36). The construct lacks a silencer element that silences 
CD4 expression in mature CD8+ T cells; consequently, 
the transgene is expressed in both CD4+ and CD8+ T cells 
(35). Flow cytometry revealed that GFP was expressed by 
 98% of CD3+ T cells in the peripheral LNs (PLNs) of 
DPEGFP mice (Fig. 1 a). The high level of GFP expression 
was further corroborated by immunofl  uorescence staining 
of PLN sections, which showed large numbers of GFP+ cells 
Figure 1.  Migratory behavior of endogenous T cells within ex-
planted PLNs. (a) Single cell suspensions of pooled PLNs from 4-mo-old 
DPEGFP mice were stained using isotype control or anti-CD3 mAbs. Gates 
were set on viable cells. (b) Frozen sections of a DPEGFP PLN were immuno-
stained for B220 (red). (c) An inguinal LN from a DPEGFP mouse was 
  explanted, and GFP+ cells were visualized by two-photon microscopy as 
described in Materials and methods, with the exception that x-y planes 
were 584 by 584 μm (resolution, 1.14 μm pixel−1) and the step size was 
4 μm. GFP+ T cells (green) were covisualized with ECM fi  bers (second 
  harmonic generation; blue). Bar, 100 μm. (d) A representative track of 
a migrating T cell is shown. The numbers indicate minutes/seconds. 
(e) Representative tracks of an analyzed region are shown. Bar, 100 μm. 
(f) The instantaneous velocities and turning angles of the T cell tracks 
were calculated. The relative frequencies of these parameters are charted. 
The arrows indicate the median values of each measurement. (g) The 
mean displacement is charted versus the square root of time.JEM VOL. 203, November 27, 2006  2751
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in the   paracortical regions, but not in B cell follicles (Fig. 1 b). 
Collectively, these results show that the DPEGFP mouse 
strain enables visualization of endogenous T cells without 
the need for adoptive transfer, which has the distinct ad-
vantage that immune responses can be studied under more 
physiologic conditions.
To set up our imaging model and compare the migratory 
behavior of endogenous polyclonal naive T cells with that 
published for TCR transgenic T cells, we performed imaging 
experiments in intact explanted PLNs under conditions 
maintaining tissue viability (28). Fig. 1 c and Videos S1 
and S2 (available at http://www.jem.org/cgi/content/full/
jem.20060710/DC1) show that by two-photon imaging, 
GFP+ cells were clearly detectable deep within the intact 
PLN, up to 300 μm below the capsule. The migratory be-
havior of GFP+ cells was then analyzed by single cell tracking 
(see Materials and methods; Fig. 1, d and e, and Videos S1 
and S2). Consistent with previous reports, naive T cells mi-
grated at a median velocity of 10.3 μm min−1 and with a 
median turning angle of 47.5° (Fig. 1 f). The linear relation-
ship between mean displacement of tracked cells and the 
square root of time indicated that polyclonal T cells migrated 
randomly (Fig. 1 g). Collectively, these data show that GFP+ 
T cells in DPEGFP mice behaved according to published 
  parameters (28–30).
TILs migrate randomly within the tumor microenvironment
To analyze the migratory and interactive behavior of TILs, 
we implanted TC-1 lung epithelial tumor cells subcutane-
ously into the fl  anks of DPEGFP mice. TC-1 cells are trans-
formed by the human papilloma virus-16 E6/E7 as well as 
c-Ha-ras oncogenes. Vaccination of mice with a replication-
defective E1/E3-deleted adenovirus human strain 5 express-
ing E7 protein induced E7-specifi  c eff  ector T cells that lyse 
E7-presenting cells (37) and cause rejection of TC-1 tumors 
(Fig. 2 a). In the absence of vaccination or when using a 
control vector expressing an unrelated protein, the tumors 
continued to grow exponentially (38 and not depicted). 
E7-MHC class I tetramer staining highlighted the infl  ux of 
  antigen-specifi  c T cells into the tumors in a time-dependent 
manner (Fig. 2 b), and histology of TC-1 tumors illustrated 
that GFP+ cells were distributed diff  usely throughout the 
tumor tissues and interspersed between tumor cells (Fig. 2 c). 
Although there was a clear diff  erence in the absolute number 
of TILs in control and vaccinated mice, their activation sta-
tus (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20060710/DC1) as well as their size (not depicted) 
were comparable.
For two-photon imaging, explanted tumors were super-
fused with temperature-controlled medium bubbled with 
95%O2/5%CO2, similarly to what has been described for ex-
planted PLNs (28, 29). GFP+ cells within progressing tumors 
in nonvaccinated animals were generally scarce. In addition, 
the motility of these cells was low (Video S3, available at 
http://www.jem.org/cgi/content/full/jem.20060710/DC1) 
and did not change when imaging was performed on days 2, 
3, and 4 after the vaccine boost (Fig. 2 d and Table I). In 
contrast, in vaccinated animals T cell motility increased mark-
edly from day 2 (Video S4) to day 4  (Video S5) after the sec-
ond vaccination (Fig. 2 d and Table I). Analysis of the 
migration pattern of nonconfi  ned GFP+ cells (defi  ned by a 
Figure 2.  T cells migrate randomly within explanted tumors and 
become highly motile during tumor regression. (a) The tumor volume 
was measured in control and vaccinated animals for up to 19 d. (b) Single 
cell suspensions of tumors were analyzed for the presence of E7-specifi  c 
CD8+ T cells using MHC class I tetramers. A representative FACS profi  le is 
shown in the top panel. The percentage of E7-specifi  c cells within total 
live cells or CD8+ T cells was determined in a time course (bottom panels). 
(c) Sections of formalin-fi  xed TC-1 and TC1-ECFP (blue) tumors were ana-
lyzed with immunofl  uorescence microscopy for the presence and distri-
bution of GFP+ cells (green). Bar, 200 μm. (d) Two-photon imaging was 
used to track and measure migratory characteristics of GFP+ T cells within 
explanted tumors (correlation between Vmean and confi  nement ratio: 
day 2: r = 0.48, P < 0.0001; day 4: r = 0.55, P < 0.0001). See Table I for 
statistical analysis of migratory parameters. (e) Mean displacement plots 
(left) and the relative frequency distribution of instantaneous velocities 
and turning angles (right) of nonconfi  ned T cells in vaccinated animals 
are depicted (*, P < 0.001).2752  T CELL BEHAVIOR WITHIN TUMORS | Mrass et al.
mean velocity (Vmean) ≥ 5 μm min−1 and a confi  nement ratio 
≥ 0.25) revealed a linear relationship between the square 
root of time and mean displacement of migrating T cells at all 
time points examined, consistent with random migration 
(Fig. 2 e, left; reference 28). However, their total displace-
ment increased from day 2 to day 4, relating to a signifi  cant 
increase in instantaneous migratory velocity (Fig. 2 e, middle 
and left). This could be associated with changes in the local 
micromilieu, such as remodeling of ECM components. In 
addition, recognition of cognate antigen may support a highly 
motile phenotype of T cells (see below). We also observed a 
decrease in turning angles of migrating T cells over time (Fig. 
2 e right), indicating a higher propensity of the cells to crawl 
in a more linear fashion between individual tracking seg-
ments. This phenomenon may be explained by a decrease in 
the number of tumors cells and hence a diminished likeli-
hood of cellular interactions that may divert the migratory path 
of T cells.
Of note, our experiments exposed the highly polarized 
morphology of actively migrating T cells, revealing lamelli-
podia at the leading edge and trailing uropods (Fig. 3 and 
Video S6, available at http://www.jem.org/cgi/content/
full/jem.20060710/DC1). In addition, as indicated by sec-
ond harmonic generation signals, T cells crawled along ECM 
fi  bers (Video S6), suggesting that these structures may be 
used as guidance cues through the interstitial space. These re-
sults are consistent with previous reports demonstrating fi  ber-
associated locomotion of MTLn3 mammary adenocarcinoma 
cells in the tumor microenvironment in vivo (39).
TILs engage in long- and short-term interactions 
with tumor cells
Next, we directly determined the nature of TIL contacts 
with TC-1 cells stably expressing enhanced cyan fl  uorescent 
Figure 3.  Migrating TILs reveal a polarized morphology and 
crawl along fi  bers of the ECM. A TC-1 tumor was explanted on 
day 4 after the vaccine boost, and T cells (green) and ECM fi  bers (blue; 
second harmonic generation signals) were visualized by two-photon 
microscopy. Imaging was performed as described in Materials and 
methods, except that x-y planes were 67.5 by 67.5 μm with 0.13 μm 
pixel−1. Note the formation of lamellipodia at the leading edge and the 
uropod at the trailing end of the cells. One individual cell is followed 
over time (indicated by arrow and track). Numbers indicate minutes/
seconds. Bar, 12 μm.
Table I.  Migratory properties of GFP+ T cells in TC-1 tumors
No. of tumors No. of regions No. of tracks Mean velocitya Confi  nement ratioa Displacementa
Sample nnn μm min−1 no unit μm
Nonvaccinated day 2 2 5 50 5.7 (4.1,8.1) 0.18 (0.08,0.34) 10.6 (5.3,29.8)
Nonvaccinated day 3 3 5 50 5.9 (4.4,7.8) 0.17 (0.10,0.31) 9.5 (6.5,22.5)
Nonvaccinated day 4 2 5 50 5.6 (3.8,7.7) 0.14 (0.09,0.25) 13.2 (5.2,18.6)
Vaccinated day 2 4 9 90 6.0 (4.9,7.9) 0.19 (0.11,0.37) 13.0 (6.5,34.0)
Vaccinated day 3 3 11 110 7.5 (5.6,9.3) 0.29 (0.16,0.49) 26.9 (13.3,49.1)
Vaccinated day 4 2 9 90 9.8 (7.6, 12.0) 0.49 (0.22,0.63) 62.1 (21.6,85.9)
Samples comparedb
Vaccinated days 2/3 P < 0.001 P < 0.05 P < 0.01
Vaccinated days 3/4 P < 0.001 P < 0.01 P < 0.001
Vaccinated days 2/4 P < 0.001 P < 0.001 P < 0.001
Nonvaccinated days 2/ 3 P > 0.05 P > 0.05 P > 0.05
Nonvaccinated days 3/4 P > 0.05 P > 0.05 P > 0.05
Nonvaccinated days 2/4 P > 0.05 P > 0.05 P > 0.05
Nonvaccinated day 2/vaccinated day 2 P > 0.05 P > 0.05 P > 0.05
Nonvaccinated day 2/vaccinated day 4 P < 0.001 P < 0.001 P < 0.001
aMedians of the analyzed migratory parameters are shown. The values in parenthesis indicate the interquartile range.
bp-values were calculated with Dunn’s multiple comparison test.JEM VOL. 203, November 27, 2006  2753
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protein (ECFP). Fig. 4 a shows three-dimensional recon-
structions of representative areas in tumors 2 and 3 d after 
the vaccine boost. The arrows in Fig. 4 a depict direct GFP+ 
T cell and ECFP+ tumor cell interactions. Dynamic analysis of 
these interactions revealed two principal interaction patterns 
between GFP+ and ECFP+ cells 2 d after the vaccine boost. 
Approximately 50% of interacting T cells engaged in fi  rm, 
long-term contacts with ECFP+ cells that lasted for the entire 
observation period (≥30 min; Video S7, available at http://
www.jem.org/cgi/content/full/jem.20060710/DC1, and 
Fig. 4, b–d). Although some of these cells remained stably in 
the same position (Fig. 4 b), others crawled slowly along the 
tumor surface without detaching  (Video S8 and Fig. 4 c). 
The other half of interacting TILs established sequential 
short-term interactions with tumor cells (Video S7 and Fig. 
4, b and d). 3 and 4 d after the vaccine boost we observed 
a decrease in the number of long-lasting contacts between 
Figure 4.  TILs engage in short- and long-term interactions with 
tumor cells in explanted tumors. GFP+ T cells (green) and TC-1-ECFP 
tumor cells (blue) were imaged simultaneously with two-photon microscopy. 
(a) Three-dimensional reconstruction of areas containing T cell–tumor cell 
contacts (arrows) 2 (left) and 3 (right) d after the vaccine boost. (b) A T cell 
undergoing a stable interaction (arrowhead) with a tumor cell and a T cell 
interacting sequentially (arrow, track) with several tumor cells are shown. 
(c) A T cell crawling along the surface of a tumor cell is depicted (track). Num-
bers in a and b indicate minutes/seconds. Bar, 13 μm. (d) The contact times 
of T cells interacting with tumor cells are charted. Open bars, conjugates that 
were tracked for the entire observation period; fi  lled bars, conjugates that 
were present either at the beginning or at the end of the observation period 
(nonvaccinated: n = 69 interactions; day 2 after boost: n = 221 inter-
actions; day 3 after boost: n = 83 interactions; day 4 after boost: n = 90 
  interactions). Arrows and numbers depict the median interaction times.
Figure 5.  Contact with T cells precedes initiation of apoptosis in 
tumor cells. (a) On day 4 after vaccination, tissue sections were stained 
with an antibody against active caspase 3 (red) and cell nuclei were 
stained with Hoechst 33258 (blue). Bar, 100 μm. (b) Explanted TC-1 ECFP 
tumors were imaged with two-photon microscopy. Bar, 26 μm. (c) The 
boxed tumor cell in b was followed in detail for 30 min. The tumor cell 
was contacted by a T cell (green, arrow) before it disintegrated. Numbers 
indicate minutes/seconds. Bar, 9 μm.2754  T CELL BEHAVIOR WITHIN TUMORS | Mrass et al.
T cells and tumor cells (Fig. 4 d; days 2/3, P < 0.001; days 
2/4, P < 0.001). We also determined the quality of TIL in-
teractions within progressing tumors. As mentioned above, 
we usually detected only a few GFP+ cells within tumor areas 
necessitating the acquisition of multiple fi  elds of view per 
  tumor. Of those GFP+ cells that interacted with tumor cells, 
approximately two thirds engaged in short-term interactions 
( 5 min), whereas one third of the conjugates remained for 
30 min or longer (Fig. 4 d). This suggests that even in unvac-
cinated animals, tumor antigen–specifi  c T cells may develop, 
but other mechanisms may prevent their expansion/activity 
resulting in progressive tumor growth (1, 7, 8).
Tumor cell disintegration follows T cell contacts
A likely consequence of T cell attack on tumors is the induc-
tion of tumor cell apoptosis, which may be mediated by direct 
cytotoxicity or indirect eff  ects on the tumor stroma. Indeed, 
4 d after the vaccine boost most tumor cells were undergoing 
apoptotic cell death as defi  ned by immunostaining for active 
caspase 3 (Fig. 5 a). By two-photon microscopy we show that 
Figure 6.  Tumor antigen–specifi  c T cells engage in direct contact 
with tumor cells and maintain high motility in the presence of cog-
nate antigen. (a) DPEGFPxOT-I CTLs were tracked in explanted EL4 and 
EG.7-OVA tumors using two-photon microscopy, and their migratory 
parameters were measured (correlation between Vmean and confi  nement 
ratio: EL4, day 3: r = 0.38, P < 0.0001; EG.7-OVA, day 3: r = 0.52, 
P < 0.0001; EL4, day 4: r = 0.55, P < 0.0001; E.G7-OVA, day 4: r = 0.54, 
P < 0.0001). (b) Shown are the dynamic changes in migratory parameters 
between days 3 and 4 after adoptive transfer. See Table II for statistical 
analysis. (c) The duration of interactions between DPEGFPxOT-I CTL and 
E.G7-OVA-ECFP or EL4-ECFP tumor cells was measured. The relative fre-
quencies of contact times are charted (EL4: n = 114 interactions; E.G7-
OVA: n = 54 interactions; P = 0.0005 determined by Mann-Whitney 
test). Arrows and numbers depict the median interaction times.
Table II.  Migratory properties of OT-I cells in EL4 and E.G7-OVA tumors
No. of tumors No. of regions No. of tracks Mean velocitya Confi  nement ratioa Displacementa
Sample nn n μm min−1 no unit μm
EL4 (day 3) 4 16 110 7.9 (6.0,9.2) 0.30 (0.19,0.44) 29.5 (14.2,46.2)
E.G7-OVA (day 3) 4 16 180 5.5 (4.0,7.5) 0.17 (0.09,0.33) 11.2 (4.9,29.0)
EL4 (day 4) 5 19 130 6.3 (4.7,8.6) 0.23 (0.12,0,39) 17.6 (6.7,38.1)
E.G7-OVA (day 4) 5 18 160 7.3 (5.4,8.7) 0.29 (0.16,0.48) 25.7 (10.6,51.4)
Samples comparedb
EL4 (day 3)/EL4 (day 4) P < 0.01 P > 0.05 P < 0.05
E.G7-OVA (day 3)/E.G7-OVA (day 4) P < 0.001 P < 0.001 P < 0.001
EL4 (day 3)/E.G7-OVA (day 3) P < 0.001 P < 0.001 P < 0.001
EL4 (day 4)/E.G7-OVA (day 4) P > 0.05 P > 0.05 P > 0.05
aMedians of the analyzed migratory parameters are shown. The values in parenthesis indicate the interquartile range.
bp-values were calculated with Dunn’s multiple comparison test.JEM VOL. 203, November 27, 2006  2755
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under control conditions TC-1 cells revealed an elongated 
spindle-shaped morphology. In contrast, in regressing tumors, 
TC-1 cells frequently had a rounded shape and a condensed 
cell body, and were shedding blebs (Fig. 5 b), phenomena 
ascribed typically to apoptotic cells in cell culture. Further-
more, we directly observed the dynamics of tumor cell apop-
tosis in situ. Over the course of 10–20 min, apparently intact 
tumor cells disintegrated revealing the morphologic hallmarks 
of apoptosis (Fig. 5 c and Video S9, available at http://www.
jem.org/cgi/content/full/jem.20060710/DC1). In some cases, 
T cell contacts preceded tumor cell apoptosis (Fig. 5 c and 
Video S9).
Recognition of cognate antigen is a critical parameter 
for T cell migration and cellular interactions within tumors
To better understand the molecular mechanisms mediating 
T cell–tumor cell interactions, we adoptively transferred in 
vitro–generated, OVA-specifi  c OT-I CD8+ eff  ector CTLs 
into animals carrying either EL4 or E.G7-OVA tumors 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20060710/DC1). Under both circumstances, OT-I cells 
continued to divide in vivo for several days in all organs ana-
lyzed, including the spleen and tumors (Fig. S2 b and not 
depicted). We also found comparable, time-dependent ac-
cumulation of OT-I eff  ector cells in EL4 and E.G7-OVA 
tumors (Fig. S2 c). Nevertheless, OT-I cells induced tumor 
regression and apoptosis only in E.G7-OVA tumors, which 
was paralleled by an increase in cell size and expression of the 
activation marker CD69 by OT-I cells isolated from E.G7-
OVA tumors (Fig. S2, d–g).
By two-photon microscopy, we observed that 3 d after 
adoptive transfer a high fraction of DPEGFPxOT-I T cells 
within E.G7-OVA, but not EL4, tumors was confi  ned in mi-
gration (Fig. 6 a). Similar to our results in the TC-1 system, 
Vmean, confi  nement ratio, as well as displacement of the whole 
cell population within the E.G7-OVA tumors increased over 
time (Fig. 6, a and b, and Table II). Moreover, the noncon-
fi  ned DPEGFPxOT-I cells in E.G7-OVA tumors gained in 
migratory velocity and displacement over time, whereas their 
turning angles decreased (Fig. S3, available at http://www.
jem.org/cgi/content/full/jem.20060710/DC1). In addition, 
DPEGFPxOT-I cells engaged in long-term interactions with 
ECFP-labeled tumor cells only in the presence of cognate 
antigen (Videos S10 and S11, and Fig. 6 c). However, it 
was also evident that DPEGFPxOT-I cells underwent short-
term interactions with EL4 cells, indicating a default target 
cell–screening program of eff  ector CTLs within target tissues 
(Video S12 and Fig. 6 c).
The substantial fraction of OT-I cells that was confi  ned in 
migration in EL4 tumors at day 4 after adoptive transfer (Fig. 
6 a) indicates that cognate signals may be necessary to main-
tain highly active motility of eff  ector T cells within target 
tissues. Alternatively, changes in the local microenvironment, 
such as destruction of tumor cells, reorganization of ECM 
fi  bers, or changes in the extracellular fl  uid, may create more 
permissive conditions for T cell motility. To distinguish be-
tween these possibilities, we transferred CD8+ eff  ector CTLs 
generated from DPEGFPxP14 cells together with unlabeled 
OT-I eff  ector cells into EL4 or E.G7-OVA tumor–bearing 
mice. CD8+ P14 T cells recognize lymphocytic choriomen-
ingitis virus glycoprotein 33-41 and therefore lack specifi  city 
for antigens within the tumors. DPEGFPxP14 cells homed to a 
similar extent to EL4 and E.G7-OVA tumors, and induction 
of tumor regression was comparable under these conditions 
as observed with OT-I T cell transfer alone (not depicted). 
Using two-photon microscopy 3 d after adoptive trans-
fer, we found that the migratory behavior of DPEGFPxP14 
cells was consistent with our previous observations with 
DPEGFPxOT-I cells (Fig. 7 a and Table S1, available at http://
www.jem.org/cgi/content/full/jem.20060710/DC1). In 
contrast, although the latter cells revealed increased migratory 
motility in E.G7-OVA tumors at day 4 (Fig. 6, a–c, and Table II), 
DPEGFPxP14 cells showed decreased migration in these 
tumors similarly to their behavior in EL4 tumors (Fig. 7 a 
and Table S1).
Because it may be argued that P14 and OT-I cells seques-
ter to diff  erent microcompartments within tumors, and, 
hence, show diff  erent migratory behavior, we also cotrans-
ferred diff  erentially labeled cells into the same tumor-bearing 
animals. To this end, antigen-primed P14 and OT-I T cells 
were transduced with retroviruses encoding for enhanced 
yellow fl  uorescent protein (EYFP) and ECFP, respectively. 
Figure 7.  Recognition of cognate antigen is necessary to sustain 
motility of TILs. (a) Effector CTLs generated from DPEGFPxP14 mice were 
transferred together with unlabeled OT-I effector CTLs into EL4 or E.G7-
OVA tumor-bearing animals. Imaging was performed 3 and 4 d later, and 
migratory characteristics were determined. See Table S1 for statistical 
analysis. (b) P14-EYFP and OT-I-ECFP CTL were cotransferred into mice 
carrying EL4 or E.G7-OVA tumors. 3 and 4 d later, cells were simultane-
ously visualized in the same fi  elds of view and migratory characteristics 
were determined. See Tables S2 and S3 for statistical analysis.2756  T CELL BEHAVIOR WITHIN TUMORS | Mrass et al.
Transduced OT-I cells induced E.G7-OVA tumor regres-
sion similarly to untransduced OT-I cells (not depicted). 
Two-photon-microscopy revealed that OT-I-ECFP and 
P14-EYFP cells homed to the same microcompartments 
within the tumors (Videos S13 and S14, available at http://
www.jem.org/cgi/content/full/jem.20060710/DC1). Fig. 7 b 
depicts the migratory characteristics of the cells visualized 
in the same fi  elds of view 3 and 4 d after adoptive transfer. 
Consistent with the results obtained with DPEGFPxP14 cells 
(Fig. 7 a), we found that P14-EYFP cells decreased their mi-
gration between days 3 and 4 regardless of the presence or 
absence of cognate antigen (Fig. 7 b and Tables S2 and S3). 
In contrast, although OT-I-ECFP cells were less active in 
EL4 tumors over time, a clear increase in their migratory be-
havior was observed in E.G7-OVA tumors between days 3 
and 4 after adoptive transfer (Fig. 7 b, Tables S2 and S3, and 
Videos S13 and S14). Because, under these conditions, P14 
and OT-I cells were exposed to the same microenvironmen-
tal cues, these results support the conclusion that the recogni-
tion of cognate antigen by TILs at the eff  ector site is important 
for the maintenance of a highly active migratory phenotype.
TILs interact physically with macrophages within tumors
Of note, we found that a considerable proportion of con-
fi  ned DPEGFPxOT-I cells within E.G7-OVA tumors did not 
contact ECFP-expressing tumor cells, but rather interacted 
with cells containing autofl   uorescent particulate material. 
Using immunofl   uorescence microscopy of tissue sections, 
we show that these cells represent F4/80+ macrophages 
(Fig. 8 a). We frequently observed that migrating CTLs in 
E.G7-OVA tumors arrested upon encounter with such mac-
rophages, and long-lasting interactions resulted (Fig. 8 b and 
Video S15, available at http://www.jem.org/cgi/content/
full/jem.20060710/DC1). These data are consistent with the 
hypothesis that antigen-presenting cells in the tumor micro-
environment cross-present tumor-associated antigens (16), 
and that T cells interact with macrophages in an antigen-
specifi  c manner (40).
Migratory behavior of TILs within tumors in vivo
Although a major advantage of our tumor explant model is 
that the imaging conditions can be kept constant between 
individual experiments, it should be noted that the lack of 
blood supply, lymphatic drainage, and innervation may have 
infl  uenced the behavior of T cells within tumors. To gain 
further insight into this issue, we analyzed DPEGFPxOT-I T 
cell migration within subcutaneously implanted EL4 tumors 
in vivo. When areas deep within the tumor were imaged 
(which represents the areas typically visualized in our explant 
model), T cells revealed a polarized morphology reminiscent 
of the cells in the explant model (Video S16, available at 
http://www.jem.org/cgi/content/full/jem.20060710/DC1). 
No diff  erence was found in migratory velocities and con-
fi  nement ratios of DPEGFPxOT-I cells under the two condi-
tions (Fig. 9 a). Moreover, displacement plots revealed that 
at the population level, TILs migrated randomly (Fig. 9 b). 
  Collectively, these results show that our explant model faith-
fully recapitulates the migratory behavior of T cells in the 
tumor microenvironment in vivo.
DISCUSSION
The success of immunotherapeutic strategies against cancer 
depends on the generation of eff   ective tumor antigen–
specifi  c T cells that must not only enter the tumor tissue, but 
must also be able to traverse the interstitial space and fi  nally 
interact with target cells. A prerequisite for the optimization 
of such strategies is the dissection of the cellular and molecu-
lar processes that ultimately lead to tumor cell destruction. 
Figure 8.  Tumor antigen–specifi  c T cells engage in physical con-
tact with macrophages in explanted tumors. (a) E.G7-OVA-ECFP 
tumors were analyzed by immunofl  uorescence microscopy 4 d after 
adoptive transfer of DPEGFPxOT-I CTL. F4/80+ cells (red) contained auto-
fl  uorescent particulate material. Contacts between T cells (green) and 
F4/80+ cells are depicted by arrows. Bars, 10 μm. (b) Two-photon imaging 
shows a crawling T cell (green) that arrests after contacting a macrophage 
(cyan) within explanted E.G7-OVA-ECFP tumors. The arresting T cell is 
highlighted with an arrow and a track. Numbers indicate minutes/seconds. 
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Our study provides a new vista of the dynamics and orches-
tration of T cell behavior within tumors, which is an essential 
step toward understanding the complex cellular interplay at 
such sites.
In this study, we made use of a tumor explant model for 
two-photon imaging of TIL behavior. This model guaran-
tees highly reproducible experimental conditions and facili-
tates imaging over prolonged periods of time without 
signifi  cant movement of the tissue, thereby reducing motion 
artifacts. Dynamic immune cell imaging in intact explanted 
tissues, including PLNs, thymic lobes, and the spinal cord, 
has now been widely used to study the migratory and inter-
active behavior of lymphocytes and dendritic cells (27, 28, 
41). However, a caveat with explanted tissue models is the 
lack of nutrient supply that may alter the performance of cells 
as compared with their counterparts in tissues in vivo. Nev-
ertheless, in the case of PLNs, careful comparisons of tissues 
in situ and in explants have revealed very similar T cell be-
havior (22, 28–30). Moreover, experiments performed in 
our study demonstrate that OT-I CTLs in EL4 tumor ex-
plants do not behave diff   erently than in tumors in vivo, 
which confi  rms the validity of our approach. This notwith-
standing, future studies will aim to dissect TIL–target cell in-
teractions within tumors in vivo and the relationship between 
TILs, tumor cells, the blood and lymphatic vasculature, as 
well as the nervous system and other cellular components of 
this particular environment.
We showed that at the population level, TILs migrated 
randomly within the tumor microenvironment both in the 
tumor explants and within tumors in situ. This fi  nding was 
unexpected, as it argues against the concept of TIL guidance 
by long-range chemokine gradients in the interstitial space 
(14, 15). Random migration of TILs is in contrast to the 
behavior of tumor cells that follow more directed migratory 
routes in vivo as an integral part of the metastatic process via 
blood/lymphatic vessel invasion (39). Thus, there appear to 
be fundamental mechanistic diff  erences in the movement of 
individual cellular components within the tumor microen-
vironment, implying the involvement of distinct regulatory 
mechanisms. In vitro studies have shown that T cells can use 
collagen fi  bers as a scaff  old for their migration (42). Thus, 
an attractive hypothesis would be that the ECM provides 
migratory cues for TILs. Consistent with this hypothesis, we 
found intimate contacts between TIL and ECM fi  bers (Fig. 3 
and Video S6). Integrins and other adhesion molecules, 
such as CD44, may be involved in this contact-dependent 
migration of TILs. Examination of T cells defi  cient in certain 
adhesion receptors will help gain further insight into these 
open questions.
From a functional viewpoint, similarly to what has been 
proposed for naive T cells in PLNs, random migration of ef-
fector T cells within target organs may maximize the likeli-
hood for target cell contacts (28, 30). Thus, it appears that 
eff  ector T cells in the periphery very actively screen their 
  microenvironment for the presence of cognate antigen. Inter-
estingly, in contrast to naive T cells within LNs, eff  ector 
CTLs required the presence of cognate antigen within the 
target site to maintain an active migratory program (Figs. 6 
and 7). This was indicated by the observation that eff  ector 
CTLs that reached the target organ in the absence of cognate 
antigen reduced migratory velocities and displacement be-
tween 24 and 48 h after tissue entry. These observations were 
consistent for TILs in progressing and regressing tumors, in-
dicating that changes in the microenvironment induced by 
an effi   cient antitumor T cell response per se are not suffi   cient 
to support high migratory motility of eff  ector CTLs. Never-
theless, it is conceivable that, after antigen contact, reduced 
tumor cell densities and/or remodeling of the ECM in re-
gressing tumors contributes to the detectable increase in T 
cell motility. Furthermore, it should be noted that although 
the viability of OT-I cells in EL4 and E.G7-OVA tumors 4 d 
after adoptive transfer was similar, we cannot exclude the 
possibility that in the absence of cognate antigen, eff  ector T 
cells undergo programmed cell death at earlier time points as 
compared with T cells that encounter antigen within tumors. 
Collectively, we propose that recognition of cognate antigen 
Figure 9.  Migratory characteristics of OT-I effector CTLs within 
EL4 tumors in vivo. EL4 cells were injected subcutaneously into the 
fl  anks of C57BL/6 mice. DPEGFPxOT-I effector CTLs were adoptively trans-
ferred 8 or 9 d later. After an additional 3 d, two-photon imaging was 
performed in surgically exposed tumors (n = 4) of anesthetized mice. 
(a) Migratory parameters were determined (circles) and are shown in com-
parison to data obtained in tumor explants (quadrangles). For both condi-
tions, 21 consecutive video frames were analyzed (Vmean [median]: in vivo: 
7.7 μm min−1, explants: 8.1 μm min−1; P = 0.33; confi  nement ratio 
[median]: in vivo: 0.37, explants: 0.39; P = 0.91). (b) The mean displacement 
of nonconfi  ned cells (Vmean ≥ 5 μm min−1, confi  nement ratio ≥ 0.5) within 
explanted tumor tissue or in vivo was calculated and charted over time.2758  T CELL BEHAVIOR WITHIN TUMORS | Mrass et al.
within tumors is a prerequisite for effi   cient migration of 
TILs. This notion bears consideration for adoptive T cell 
transfer approaches, as it may suggest that in the absence of 
cognate antigen, CTLs rapidly lose their high speed target–
searching capability.
T cell infi  ltration into tumors in nonvaccinated animals 
was sparse. Those T cells that successfully entered this micro-
environment were largely inactive in their migration, and 
their migratory behavior did not change over the course of 
3 d. This indicates that the cells either did not reencounter 
cognate antigen in the tumors (which may be necessary for 
their reactivation directly within the eff  ector site; see also Fig. 6) 
and/or the presence of factors that inhibit the active migra-
tion of T cells. However, it is interesting to note that some 
TILs even in progressing tumors were found to stably interact 
with tumor cells, which may favor the hypothesis of migra-
tory suppression under these conditions.
The precise identity of the cells targeted by TILs, as 
well as the exact mechanisms by which T cells induce tu-
mor regression, has been matter of long-standing debate. It 
has been suggested that MHC-restricted recognition of anti-
gens on tumor cells within the tumor microenvironment is 
crucial for T cell–mediated tumor rejection (7). However, 
an emerging concept postulates the importance of antigen 
cross-presentation by stromal cells for the induction of tumor 
regression (16). Our study reconciles these claims by dem-
onstrating that TILs physically contact both tumor cells and 
tissue macrophages.
The fact that approximately half of the observed cognate 
antigen–dependent interactions of TILs with tumor cells 
were long-lasting would be consistent with direct cytotoxic-
ity by TILs via the secretion of proapoptotic factors, includ-
ing granzymes and perforin. Moreover, the protracted nature 
of these interactions may indicate the formation of immuno-
logic synapses (43), which have also been demonstrated to 
develop, for instance, between eff  ector CTLs and virus-
  infected target cells in vivo (44). It will be interesting to com-
pare the dynamics of formation as well as the molecular 
composition of immunologic synapses between naive T cells 
and antigen-presenting cells during the priming phase, and 
eff  ector CTLs and target cells during the eff  erent phase of the 
immune response. This will give important insights into the 
mechanisms of target cell destruction by TILs.
The other half of TIL–tumor cell interactions was short-
lived, and TILs often engaged with multiple consecutive 
tumor cells within short periods of time. Similar cellular en-
counters that occur between T cells and dendritic cells in 
collagen matrices in vitro are suffi   cient to induce activation 
of T cells (45). Thus, it is conceivable that eff  ector T cells 
also integrate signals from such consecutive interactions 
with tumor cells necessary for maintaining their activated 
state and/or the induction of cytokine production (for 
example, IFN-γ).
Recognition of cross-presented antigen on macrophages 
by TILs could result in TIL activation followed by cytokine 
production (for instance, IFN-γ). Reciprocally, the secretion 
of IFN-γ may lead to the activation of macrophages and in-
duce the production of tumoricidal mediators, including re-
active oxygen species or nitric oxide (46). Interestingly, 
IFN-γ may be released directly into the immunologic syn-
apse, which could establish a high local concentration of the 
cytokine and preferential activation of the adjacent macro-
phage (47). Of note, stromal cells may themselves be targets 
for cytotoxic attack by TILs. Indeed, a recent study has shown 
that destruction of CD11b+ stromal cells that cross-present 
tumor antigen can contribute to the elimination of estab-
lished tumors in which tumor cells had lost the capability to 
express target antigen (antigen loss variants; reference 17).
In conclusion, our results provide evidence that direct in-
teractions of TILs with antigen-presenting cells and tumor 
cells are integral elements of the eff  ector phase of the antitu-
mor immune response. Our model provides the basis for fur-
ther elucidation of the molecular machinery involved in the 
migration of TILs as well as their interactions with target cells 
within tumors.
MATERIALS AND METHODS
Mice. We used a transgenic mouse strain (DPEGFP; crossed to the C57BL/6 
background for 10 generations) in which GFP is expressed by all T cells. 
OT-I mice (The Jackson Laboratory) and P14 mice (provided by E.J. Wherry, 
The Wistar Institute, Philadelphia, PA) were crossed with DPEGFP mice 
(DPEGFPxOT-I, DPEGFPxP14). C57BL/6 wild-type mice were obtained 
from Charles River Laboratories. Experimental protocols were approved by 
the Institutional Animal Care and Use Committee of The Wistar Institute.
Reagents. CD3, IgG, L-selectin, CD44, CD69, and CD8 antibodies 
(BD Biosciences); an anti-active caspase 3 rabbit serum (R&D Systems); 
  Alexa 546–conjugated goat anti–rabbit IgG; CFSE (Invitrogen); and bis-
benzimide (Hoechst 33258; Sigma-Aldrich) were used. An E7-specifi  c 
MHC class I tetramer was provided by S. Albelda (University of 
Pennsylvania, Philadelphia, PA). SIINFEKL peptide was purchased from Alpha 
Diagnostic International.
Tumor experiments. EL4 and E.G7-OVA thymoma cells were purchased 
from the American Type Culture Collection. TC-1 was obtained from T.C. 
Wu (Johns Hopkins University, Baltimore, MD). TC-1-ECFP cells were 
generated by transfection with a pcDNA3.1/ECFP construct. EL4-ECFP 
and E.G7-OVA-ECFP lines were generated using a retroviral plasmid con-
taining ECFP (provided by L. Beverly and A. Capobianco, The Wistar 
  Institute). Individual ECFP-expressing clones were selected that had similar 
in vitro and in vivo growth characteristics as the parental cell line (not 
  depicted and Fig. S4).
For all experiments, 106 tumor cells were injected subcutaneously in the 
fl   ank of mice. TC-1 tumor-carrying mice were injected intramuscularly 
with adenovirus human strain 5–expressing E7 protein (2 × 107 pfu) in 100 μl 
PBS or with PBS alone 5 and 12 d after tumor cell inoculation. EL4 or 
E.G7-OVA tumor-carrying mice were injected intravenously with 2 × 107 
DPEGFPxOT-I eff  ector CTLs 8 d after tumor injection. In some experi-
ments, OT-I eff  ector CTLs were mixed with DPEGFPxP14 (2 × 107 each). 
Eff  ector CTLs were generated as described previously (48). In brief, spleno-
cytes from TCR transgenic mice were stimulated with the respective cog-
nate peptides (1 μg/ml) for 1 h, washed, and incubated for 2 d. Thereafter, 
cells were cultured in the presence of 20 ng/ml IL-2 for an additional 5–6 d. 
Medium was changed every other day.
For covisualization experiments, P14 and OT-I cells were stimulated 
with peptides as described above. 24 h later, the cells were transduced with 
MIGR1-based retroviral plasmids containing either the ECFP or EYFP 
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previously published protocols (49). In brief, 3–5 × 106 cells were resus-
pended in 1 ml of viral supernatant containing 8 μg/ml polybrene and cen-
trifuged at 6,000 g for 90 min at 25°C. Thereafter, the cells were cultured in 
the presence of 20 ng/ml IL-2. Media was changed daily until use.
Flow cytometry. Excised tumors were cut into small pieces and incubated 
in HBSS containing 10 mg ml−1 collagenase D (Roche) and 1 mg ml−1 
DNase I (Roche). Single cell suspensions were stained and analyzed using a 
FACSCalibur fl  ow cytometer (Becton Dickinson). Data were analyzed with 
FlowJo software (Tree Star).
Immunofl  uorescence staining. PLNs and tumor tissue were either fi  xed 
overnight in 4% formaldehyde/10% sucrose at 4°C (for analysis of GFP+ 
cells) or directly snap-frozen in liquid nitrogen. Immunostaining was per-
formed as described previously (50).
Tissue preparation for live cell imaging. For the tissue explant model, 
mice were killed by CO2 asphyxiation and the desired tissues were removed. 
Subcutaneously implanted tumors were usually well demarcated and could 
be separated easily from surrounding fat and connective tissue, thus inducing 
only minimal mechanical stress. Immediately after preparation, tissues were 
transferred into an imaging chamber (Warner Instruments) and stabilized ei-
ther with superglue (LNs) or with a mesh (tumors). Tissues were continu-
ously superfused with RPMI medium containing 10% fetal bovine serum 
and bubbled with 95% oxygen and 5% carbon dioxide as described previ-
ously (28, 29). The temperature was maintained at 36.5°C.
For in vivo imaging of tumors, we adapted a previously established 
model of subiliac LN preparation/imaging (51). In brief, tumors were im-
planted into the fl  anks of C57BL/6 mice, and DPEGFPxOT-I eff  ector cells 
were transferred 8 or 9 d later. After an additional 3 d, mice were anesthe-
tized and a skin fl  ap with the embedded tumor was prepared by separating 
the skin from the underlying abdominal wall. This procedure exposed the 
surface of the tumors without the need for further dissection of connective 
tissue or fat cells, thus avoiding damage to feeding and draining blood vessels. 
The preparation was then immersed in prewarmed physiologic saline solu-
tion (36.5°C). The temperature was controlled and adjusted as needed.
Two-photon microscopy and image analysis. Two-photon imaging 
was performed on a Prairie Technology Ultima System attached to an 
Olympus BX-51 fi  xed-stage microscope equipped with 20× (NA 0.95) and 
40× (NA 0.8) water immersion objectives. The setup included external 
nondescanned dual-channel refl  ection/fl  uorescence detectors and a diode-
pumped, wideband mode–locked Ti:Sapphire femtosecond laser (720–950 
nm, <140 fs; 90 MHz; Coherent Chameleon).
The samples were exposed to polarized laser light at a wavelength of 920 
(T cell migration studies) or 890 nm (T cell–target cell interaction studies). 
Emitted light was separated with a fi  lter set (dichroic mirror, 495 nm; band-
pass, 520/35 nm; bandpass, 460/50 nm). In experiments where ECFP- and 
EYFP-expressing cells were covisualized, an alternative fi  lter set was used 
(dichroic mirror, 515 nm; bandpass, 485/15 nm; bandpass, 522.5/12.5 nm). 
z-stacks of a series of x-y planes of 284 by 284 μm at a resolution of 0.55 μm 
pixel−1 (migration studies) or of 142 by 142 μm at a resolution of 0.28 μm 
pixel−1 (interaction studies) with a total thickness of 30 μm (step size, 6 μm) 
were captured every 25 s using Prairie View acquisition software (Prairie 
Technologies). Typically, the tumor samples were imaged at a depth of 
50–150 μm below the surface.
Three-dimensional image stacks were transformed into movies using 
Volocity software (Improvision). Mean migration velocities, cellular dis-
placement, and confi  nement ratios (total length of track divided by distance 
between starting and end point) were calculated for 12’55” (tumors) or 7’5” 
(LNs) as described previously (25). Instantaneous velocity was defi  ned as the 
velocity of a cell during a 50” observation period (25). The turning angle 
was defi  ned as the deviation of one segment of a track from the preceding 
one (25). Measurements were typically performed on 31 consecutive frames 
of the videos, with the exception of the in vivo tumor experiments, where 
21 frames were evaluated. For the measurement of T cell–target cell interac-
tions, T cells in a fi  eld of view were randomly selected at the start of the ac-
quisition period and followed until they either left the fi  eld of view or until 
the end of the imaging sequence. Cellular contacts were defi  ned as the ab-
sence of a space (empty pixels) between fl  uorescent T cells and tumor cells 
or macrophages in the same x-y plane. Imaging for these experiments was 
conducted for 30 min.
Statistical analysis. For group comparisons of normally distributed samples 
(KS test), one-way ANOVA followed by the Bonferroni test was used. Other-
wise, groups were compared using the Kruskal-Wallis followed by Dunn’s 
multiple comparison test. For comparisons of two samples, the Student’s t test 
(normally distributed) or the Mann-Whitney test (not normally distributed) 
was used. A diff  erence was considered signifi  cant if P < 0.05. The error 
bars in all charts represent standard errors of the mean. To test if values 
for the mean velocity correlated to the confi  nement ratio, Spearman’s rank 
correlation coeffi   cient was calculated.
Online supplemental material. Fig. S1 demonstrates that a high fraction 
of TILs both in vaccinated and nonvaccinated tumors is activated. Fig. S2 
characterizes the growth behavior of EL4 and E.G7-OVA tumors as well as 
TIL phenotype and function after adoptive transfer. Fig. S3 shows the mi-
gratory properties of adoptively transferred nonconfi  ned TILs in EL4 and 
E.G7-OVA tumors. Fig. S4 analyzes the growth behavior of TC-1 ECFP 
tumors in vaccinated and nonvaccinated mice, and characterizes the migra-
tory properties of TILs. Table S1 shows the motility characteristics of P14 
cells within EL4 and E.G7-OVA tumors. Table S2 depicts the motility of 
  simultaneously imaged P14-EYFP and OT-I-ECFP cells in EL4 tumors. 
Table S3 provides the motility of P14-EYFP and OT-I-ECFP cells in 
E.G7-OVA tumors. Videos S1 and S2 show endogenous naive T cells 
  migrating within a PLN. Videos S3–S5 show migration of endogenous TILs in 
TC-1 tumors. Video S6 shows a high resolution sequence of a TIL crawling 
along an ECM fi  ber. Videos S7 and S8 show TILs in vaccinated mice that 
interact with tumor cells. Video S9 shows a tumor cell in a vaccinated mouse 
that disintegrates after being targeted by TILs. Videos S10–S12 show adop-
tively transferred OT-I cells interacting with E.G7-OVA or EL4 tumor cells. 
Videos S13 and S14 show P14-EYFP and OT-I-ECFP TIL simultaneously 
imaged within E.G7-OVA tumors. Video S15 shows adoptively transferred 
OT-I cells interacting with a macrophage. Video S16 shows migrating TILs 
within an EL4 tumor in vivo. The online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20060710/DC1.
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